Dow Jones
37.798,97 +63,86 (+0,17%) Nasdaq
15.865,25 -19,77 (-0,12%) Nikkei 225
38.471,20 -761,60 (-1,94%) EUR/USD
1,0619 -0,0007 (-0,06%) Bitcoin EUR
60.056,49 +379,96 (+0,64%) CMC Crypto 200
885,54 0,00 (0,00%)
Amicus Therapeutics, Inc. (0HF9.L)
| Chiusura precedente | 10,77 |
| Aperto | 10,69 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 10,66 - 10,69 |
| Intervallo di 52 settimane | 9,74 - 14,57 |
| Volume | |
| Media Volume | 814 |
| Capitalizzazione | 31,252M |
| Beta (5 anni mensile) | 0,76 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,97 |
| Prossima data utili | 08 mag 2024 - 13 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireAmicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters highlighting its development program for Pompe disease will be included at the 28th Annual Congress of the World Muscle Society (WMS), being held October 3-7, 2023 in Charleston, SC. Oral Presentation: Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa + miglustat in patients with late-onset Pompe disease previously treated with algl
- GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases, today announced that it has entered into a definitive agreement for a $430 million financing collaboration with funds managed by Blackston
GlobeNewswireAmicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
Pombiliti + Opfolda Logo Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults Living with Late-onset Pompe Disease Amicus Therapeutics to Host Conference Call Today at 12:00 p.m. ET PHILADELPHIA, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has approved Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (migl
